Table 1 Completed clinical trials evaluating different stem cells for myocardial ischemia (MI)
From: Exosome-bearing hydrogels and cardiac tissue regeneration
Clinical trial | Completed date | Cell source | Delivery pathway | Outcome(s) |
|---|---|---|---|---|
TOPCARE-AMI [4] | 2002 | Peripheral progenitor cells/bone marrow MSCs | Intracoronary | Ejection fraction↑, infarct size↓ |
TOPCARE-AMI [5] | 2004 | Peripheral progenitor cells/ bone-marrow MSCs | Intracoronary | LVEF↑, infarct size↓ |
BOOST [6] | 2004 | Autologous bone marrow MSCs | Intracoronary | LVEF↑ |
MAGIC [7] | 2004 | Peripheral progenitor cells | Intracoronary | Myocardial perfusion↑, LVEF↑ |
IACT [8] | 2005 | Autologous mononuclear bone marrow cells | Intracoronary | LVEF↑, infarct size↓, wall movement velocity↑ |
Acute Myocardial Infarction [9] | 2006 | Autologous bone marrow MSCs | Intracoronary | Exercise time↑, peak heart rate↑ |
REPAIR-AMI [10] | 2006 | Autologous bone marrow MSCs | Intracoronary | LVEF↑, infarct size↓, revascularization↑ |
HEBE [11] | 2007 | Peripheral progenitor cells/bone marrow MSCs | Intracoronary | Non-significant changes in left ventricular volumes, mass, and infarct size |
MYSTAR [12] | 2008 | Autologous bone marrow MSCs | Intra-myocardial and intracoronary | LVEF↑, infarct size↓ |
REGENT [13] | 2008 | Autologous bone marrow MSCs | Intracoronary | No significant improvement in LV ejection fraction |
Patients with acute MI [14] | 2009 | Autologous bone marrow MSCs | Intra-myocardial | LVEF↑, infarct size↓ |
SEED-MSC [15] | 2010 | Autologous bone marrow MSCs | Intracoronary | LVEF↑ |
Apollo [16] | 2010 | Adipose tissue MSCs | Intracoronary | No significant improvement in LV ejection fraction and infarct size |
CADUCEUS [17] | 2011 | Autologous cardiosphere-derived stem cells | Intracoronary | Infarct size↓ |
Patients with acute MI [18] | 2012 | Human Wharton’s jelly-derived MSCs | Intracoronary | LVEF↑, infarct size↓ |
The Late TIME Study [19] | 2012 | Autologous bone marrow mononuclear cells | Intracoronary | No significant improvement in LV ejection fraction and infarct size |
COMPARE CPM-RMI [20] | 2012 | Autologous bone marrow CD133+ cells | Intra-myocardial | LVEF↑, infarct size↓, viability↑ |
SCAMI [21]. | 2013 | Autologous bone-marrow MSCs | Intracoronary | LVEF↑ |
SCIPIO [22] | 2013 | Cardiac stem cells | Intracoronary | LVEF↑, infarct size↓ |
REPAIR-AMI [23] | 2014 | Autologous bone marrow MSCs | Intracoronary | Unknown death or rehospitalization↓ |
MyStromalCell [24] | 2014 | Autologous VEGF-A165-stimulated adipose tissue MSCs | Intra-myocardial | No significant outcome |
PoseidonDCM [25] | 2016 | Autologous and allogeneic bone-marrow MSCs | Transendocardially | Cardiac function↑ in the allogeneic-treated group |
CAREMI [26] | 2016 | Allogeneic human cardiac stem cells | Intracoronary | No significant improvement in LV volumes, ejection fraction, or regional wall motion |
PreSERVE-AMI [27] | 2017 | Autologous bone marrow MSCs | Intracoronary | LVEF↑, infarct size↓ |
Patients with elevated ST [28] | 2018 | Autologous bone marrow mononuclear cells | Intracoronary | No significant improvement in LVEF and infarct size |